December 2016
-
Aptar Pharma has announced the appointment of Jean-Marc Pardonge as President of Aptar Pharma’s Prescription Division, succeeding Salim Haffar, and as General Manager of Aptar Stelmi. Aptar’s prescription division develops and manufactures a range of… Read more . . .
-
Vienna, Austria-based Marinomed has announced the granting of Chinese patent No. CN101678040, titled “Antiviral Polymer,” for a component of its Mavirex technology platform. According to the company, the patent covers prevention and treatment of the… Read more . . .
-
Copley Scientific has officially launched the SCP5 Super Capacity Pump which is capable of generating flow rates as high as 100 L/min for cascade impaction of dry powder inhalers. The new model, a 1.5 kW… Read more . . .
-
OptiNose has announced Phase 3 results from a study of its sumatriptan nasal powder for the treatment of migraine, as well as a grant from the Research Council of Norway to study nasal delivery of… Read more . . .
-
Pearl Therapeutics has raised $65 million from current investors to enable initiation of Phase 3 trials for its PT003 glycopyrrolate (GP)/formoterol fumarate (FF) MDI for the treatment of COPD, the company says. This round of… Read more . . .
-
According to Savara Pharmaceuticals, the company’s AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients has been granted orphan drug status by the FDA. Aerovanc inhalation powder, which… Read more . . .
-
PPD is currently looking to recruit a Scientist to be based in our cGMP Lab in Athlone, Ireland. The basic purpose of the Scientist role is to perform a variety of complex sample preparation and… Read more . . .
-
QVA149 developers Vectura and Sosei have confirmed that Novartis has submitted an application for Japanese approval of the inhaled fixed dose combination of indacaterol maleate and glycopyrronium bromide for the treatment of COPD. Novartis, which… Read more . . .
-
Submit 500 word abstracts by December 14, 2012 online at Read more . . .
-
Boehringer Ingelheim has announced an €85 million expansion to the BI microParts GmbH inhaler manufacturing facililty in Dortmund, Germany meant to double its annual production of Respimat inhalers to 44 million by 2015. Filling of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland